6533b820fe1ef96bd1279b3d
RESEARCH PRODUCT
Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells.
Rosario HeckMatthias BrosFriedrich FoersterLeonard KapsJohn C. CastleM. AslamSebastian BoegelUgur SahinSebastian RosigkeitMustafa DikenAndrea TuettenbergDetlef SchuppanStephanie StroblGeetha PickertErnesto BockampNina Rüsselsubject
0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyNK cellsMajor histocompatibility complexcancer immunologyliverlcsh:RC254-282BALB/cImmune toleranceMetastasis03 medical and health sciencesImmune systemMHC class ImedicineImmunology and Allergymetastasisinnate immunityOriginal ResearchInnate immune systembiologybiology.organism_classificationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmacrophages030104 developmental biologyOncologyCancer cellCancer researchbiology.proteinlcsh:RC581-607description
ABSTRACT The B16F10 murine melanoma cell line displays a low expression of MHC class I molecules favoring immune evasion and metastases in immunocompetent C57 BL/6 wild-type mice. Here, we generated metastases to the liver, an organ that is skewed towards immune tolerance, by intrasplenic injection of B16F10 cells in syngeneic C57 BL/6 compared to allogeneic Balb/c mice. Surprisingly, Balb/c mice, which usually display a pronounced M2 macrophage and Th2 T cell polarization, were ∼3 times more susceptible to metastasis than C57 BL/6 mice, despite a much higher M1 and Th1 T cell immune response. The anti-metastatic advantage of C57 BL/6 mice could be attributed to a more potent NK-cell mediated cytotoxicity against B16F10 cells. Our findings highlight the role of NK cells in innate anti-tumor immunity in the context of the liver – particularly against highly aggressive MHC I-deficient cancer cells. Moreover, the B16F10 model of melanoma liver metastasis is suited for developing novel therapies targeting innate NK cell related immunity in liver metastases and liver cancer.
year | journal | country | edition | language |
---|---|---|---|---|
2017-12-26 | Oncoimmunology |